| Primary | Percentage of Clinical Cure (Success) at Test of Cure Visit(Clinical Per Protocol Population) | Cure=Signs&symptoms(S&S) of infection return to normal baseline level or clin improvement requiring no other antibiotics(AB); Failure=other AB due to S&S of acute infection persisted/worsened,new clinical S&S of acute infection,or clinical/radiological evidence of pneumonia developed during treatment; percent = # of cure or failure/total # of sub | Clinical Per Protocol-all randomized subjects who were clinically eligible; received at least 80% of study med; no concomitant systemic antibiotics with activity against Acute Exacerbation of Chronic Bronchitis (AECB) pathogens, assessment made in appropriate visit window. | Posted | | Number | | percent | | Test of Cure (TOC) Visit (Day 12-19) | | | | ID | Title | Description |
|---|
| OG000 | Azithromycin | Azithromycin SR (2.0 grams, microspheres formulation) was administered orally as single dose in form of an oral suspension on Day 1 | | OG001 | Moxifloxacin | Moxifloxican (400 milligrams)were administered orally as capsules once daily for five days. |
| | | Title | Denominators | Categories |
|---|
| Cure | | | | Failure | | |
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| 95% Confidence Interval (CI) for the difference in cure rates will be constructed using a method of linear stratification that weights according to the reciporcal of the variance. Stratification will be by steriod use at time of randomization. | | | | | Risk Difference (RD) | -0.9 | | | | 95 | -5.8 | 3.9 | | | Risk difference is the difference in percentage of participants with cure and the 95% Confidence Interval | Yes | Non-Inferiority or Equivalence | Non-inferiority will be declared if the lower bound of the 95% CI around the difference in clinical success rates is greater than -10% |
|
| Secondary | Percentage of Clinical Cure (Success) at Test of Cure Visit (Full Analysis Set) | Clinical response (Cure vs Failure) at the TOC visit for the Full Analysis Set (FAS), Cure=Signs&symptoms(S&S) of infection return to normal baseline level or clin improvement requiring no other antibiotics(AB); Failure=other AB due to S&S of acute infection persisted/worsened,new clinical S&S of acute infection,or clinical/radiological evidence of pneumonia developed during treatment; percent = # of cure or failure/total # of sub | Full Analysis Set (FAS) is all randomized subjects who received at least 1 dose of study medication. | Posted | | Number | | Percent | | Test of Cure (TOC) Visit (Day 12-19) | | | | ID | Title | Description |
|---|
| OG000 | Azithromycin | Azithromycin SR (2.0 grams, microspheres formulation) was administered orally as single dose in form of an oral suspension on Day 1 | | OG001 | Moxifloxacin | Moxifloxican (400 milligrams)were administered orally as capsules once daily for five days. |
| |
| Secondary | Percentage of Clinical Cure (Success)at Test of Cure Visit(Clinically Eligible Set) | Clinical Response at TOC Visit for clinically Eligible Subjects, Cure=Signs&symptoms(S&S) of infection return to normal baseline level or clin improvement requiring no other antibiotics(AB); Failure=other AB due to S&S of acute infection persisted/worsened,new clinical S&S of acute infection,or clinical/radiological evidence of pneumonia developed during treatment; percent = # of cure or failure/total # of sub | Clinically eligible compromised of subjects from FAS with diagnosis of chronic bronchitis, clinical evidence of AECB based on S&S, & a neg chest radiograph for pneumonia based on radiologist opinion | Posted | | Number | | Percent | | Test of Cure (TOC) Visit (Day 12-19) | | | | ID | Title | Description |
|---|
| OG000 | Azithromycin | Azithromycin SR (2.0 grams, microspheres formulation) was administered orally as single dose in form of an oral suspension on Day 1 | | OG001 | Moxifloxacin | Moxifloxican (400 milligrams)were administered orally as capsules once daily for five days. |
| |
| Secondary | Percentage of Bacteriologic Response at Test of Cure Visit | Bacteriogical response assessed on per pathogen basis for Bacteriologic Per Protcol (BPP) set at TOC Visit. If no repeat culture, response is presumed from sponsor assessment of clinical response. Eradication =# of pathogens eradicated at TOC/N; Persistence =# of pathogens persistent at TOC/N; N=# of unique pathogens identified at baseline | Bacteriologic per protocol set is compromised of subjects from the Clinical Per Protocol set with a baseline bacterial pathogen. The number of participants is the number of unique pathogens identified at baseline. | Posted | | Number | | Percent | | Test of Cure (TOC) Visit (Day 12-19) | | | | ID | Title | Description |
|---|
| OG000 | Azithromycin | Azithromycin SR (2.0 grams, microspheres formulation) was administered orally as single dose in form of an oral suspension on Day 1 | | OG001 | Moxifloxacin | Moxifloxican (400 milligrams)were administered orally as capsules once daily for five days. |
| |
| Secondary | Time Taken for First Quartile (25%) of Subjects to Have AECB Recurrence | Subject is considered to have AECB recurrence if they had a clinical response of cure at the TOC visit and then met the definition of AECB during the follow-up period. | Time to AECB recurrence will be analyzed for the FAS using survival analysis methods to account for censored observations. Subjects are censored at the date last known to have not experienced a recurrence. Median time to recurrence will be estimated using the Kaplan-Meier method. | Posted | | Number | | Days | | Number of Days | | | | ID | Title | Description |
|---|
| OG000 | Azithromycin | Azithromycin SR (2.0 grams, microspheres formulation) was administered orally as single dose in form of an oral suspension on Day 1 | | OG001 | Moxifloxacin | Moxifloxican (400 milligrams)were administered orally as capsules once daily for five days. |
| |
| Secondary | Change From Baseline in Clinical COPD Questionnaire(CCQ)Total Score | CCQ was developed to measure health status of Chronic obstructive pulmonary disease (COPD) subjects. 10 items divided into 3 domains: symtoms, functional state, and mental state. Subject record their experiences during last 24 hrs. 7 pt scale - 0=asymptomatic and 6=extremely symptomatic/totally limited; change=mean score at observation minus mean score at baseline | Analysis on Full Analysis Set, Last Observation Carried Forward (LOCF)-missing values at TOC visit will be imputed by carrying forward the last post-baseline observation; total score calculated by deriving the simple average of relevant items, total score is set to missing if 1 or more domain scales cannot be derived. | Posted | | Least Squares Mean | Standard Error | Score on Scale | | Test of Cure (TOC) Visit (Day 12-19) | | | | ID | Title | Description |
|---|
| OG000 | Azithromycin | Azithromycin SR (2.0 grams, microspheres formulation) was administered orally as single dose in form of an oral suspension on Day 1 | | OG001 | Moxifloxacin | Moxifloxican (400 milligrams)were administered orally as capsules once daily for five days. |
| |
| Secondary | Change From Baseline in Clinical COPD Questionnaire(CCQ)Symptoms Score | 1 of 3 domains that combined into the CCQ Total score. Items 1,2,5,and 6 address symptoms. Subject record their experiences during last 24 hrs. 7 pt scale - 0=asymptomatic and 6=extremely symptomatic; change=mean score at observation minus mean score at baseline | Analysis on Full Analysis Set, LOCF - missing values at the TOC visit will be imputed by carrying forward the last post baseline observation. Domain score is calculated by deriving the simple average of the relevant items, at least 75% of items must be non-missing to derive the domain score | Posted | | Least Squares Mean | Standard Error | Score on Scale | | Test of Cure (TOC) Visit (Day 12-19) | | | | ID | Title | Description |
|---|
| OG000 | Azithromycin | Azithromycin SR (2.0 grams, microspheres formulation) was administered orally as single dose in form of an oral suspension on Day 1 | | OG001 | Moxifloxacin | Moxifloxican (400 milligrams)were administered orally as capsules once daily for five days. |
| |
| Secondary | Change From Baseline in Clinical COPD Questionnaire(CCQ)Functional State Score | 1 of 3 domains that combined into the CCQ Total score. Items 7,8,9, and 10 address functional state. Subject record their experiences during last 24 hrs. 7 pt scale - 0=asymptomatic and 6=extremely; change=mean score at observation minus mean score at baseline | Analysis on Full Analysis Set, LOCF-missing values at the TOC visit will be imputed by carrying forward the last post baseline observation. Domain score is calculated by deriving the simple average of the relevant items, at least 75% of items must be non-missing to derive the domain score | Posted | | Least Squares Mean | Standard Error | Score on Scale | | Test of Cure (TOC) Visit (Day 12-19) | | | | ID | Title | Description |
|---|
| OG000 | Azithromycin | Azithromycin SR (2.0 grams, microspheres formulation) was administered orally as single dose in form of an oral suspension on Day 1 | | OG001 | Moxifloxacin | Moxifloxican (400 milligrams)were administered orally as capsules once daily for five days. |
| |
| Secondary | Change From Baseline in Clinical COPD Questionnaire(CCQ)Mental State Score | 1 of 3 domains that combined into the CCQ Total score. Items 3 and 4 address mental state. Subject record their experiences during last 24 hrs. 7 pt scale - 0=asymptomatic and 6=extremely; change=mean score at observation minus mean score at baseline | Analysis on Full Analysis Set, LOCF-missing values at TOC will be imputed by carrying forward the last post-baseline observation; Domain score is calculated by deriving the simple average of the relevant items, both mental state items must be non-missing to derive a mental state score | Posted | | Least Squares Mean | Standard Error | Score on Scale | | Test of Cure (TOC) Visit (Day 12-19) | | | | ID | Title | Description |
|---|
| OG000 | Azithromycin | Azithromycin SR (2.0 grams, microspheres formulation) was administered orally as single dose in form of an oral suspension on Day 1 | | OG001 | Moxifloxacin | Moxifloxican (400 milligrams)were administered orally as capsules once daily for five days. |
| |